Regeneron wins FDA approval for first gene therapy to restore hearing in deaf children, will offer for free
Regeneron Pharmaceuticals received FDA approval for the first gene therapy designed to restore hearing in children born with a rare genetic form of deafness. The one-time treatment targets a condition affecting about 50 babies annually in the United States. Regeneron announced it will provide the therapy free of charge. The approval marks a milestone in gene therapy for sensory disorders.
Key facts
- Regeneron won FDA approval for the first gene therapy to restore hearing in deaf children
- The therapy is a one-time treatment
- It targets a rare genetic condition
- About 50 babies are born each year in the U.S. with the condition
- Regeneron will offer the therapy for free
Entities
Institutions
- Regeneron Pharmaceuticals
- FDA
Locations
- United States
Sources
- Quartz —